Discerning Hope from Hype Related to Novo Nordisk Glucose-Responsive Insulin

Below is a copy of an investor report (seeHERE) on Novo Nordisk from the Wall Street investment bank known as Credit Suisse (the New York-based research business of the Swiss banking giant which mainly serves billionaire clients was formerly known as First Boston). I will discern my take-aways as it pertains to the few notes about Novo Nordisk ' s much-hyped (by the company itself) glucose-responsive insulin. There is some progress, but it is by no means a done deal.Novo Nordisk AS Feedback from London Post 3Q 2021 Management Meeting on ScribdOn November 4, 2021, Credit Suisse attended a London sell-side meeting with Novo Nordisk A/S ' s Karsten Knudsen (CFO), Camilla Sylvest (EVP Commercial Strategy) and Martin Lange (EVP Development). Most of the dialogue was about the company ' s GLP business (Ozempic, Saxenda, Xultophy [iself a combo drug consisting of Novo ' s GLP-1 agonist and its basal insulin analogue degludec sold under the brand name Tresiba] and Wegovy -- all of which are New& Improved versions of the company ' s " original " GLP-1 agonist which was branded as Victoza, and that product was little more than an improved version of the biologic drug branded as Byetta which the old Amylin Pharmaceuticals commercialized before that company ' s ultimate demise; most of its intellectual property assets were acquired by AstraZeneca, although Lilly kept some developed during its joint venture with Amylin. Today, Lilly sells a new and improved version of its own GLP-1 ag...
Source: Scott's Web Log - Category: Endocrinology Tags: Credit Suisse glucose responsive insulin Novo Nordisk Smart Insulin 2021 2022 SmartCells Source Type: blogs